Literature DB >> 21349413

Measuring the relationship of quality of life and health status, including tumor burden, symptoms, and biochemical measures in patients with neuroendocrine tumors.

Etta Vinik1, Maria P Silva, Aaron I Vinik.   

Abstract

The measurement of health-related quality of life (HRQOL) has become essential for evaluating the impact of neuroendocrine tumors (NETs) on symptoms and social, emotional, psychological, and physical functioning of patients who harbor these tumors. This article describes instruments that have been developed to capture the spectrum of symptoms and the impact of the disease on their overall well-being. The authors discuss the importance of adequate sensitivity, specificity, and reproducibility and the value of psychometric factor analysis to explore the domains that embrace the manifestations of these tumors as well as aspects of the instruments that reflect tumor burden, biochemical, and hormonal status.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21349413     DOI: 10.1016/j.ecl.2010.12.008

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  11 in total

1.  Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib.

Authors:  Aaron I Vinik; Eric Raymond
Journal:  Therap Adv Gastroenterol       Date:  2013-09       Impact factor: 4.409

2.  Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.

Authors:  George A Fisher; Edward M Wolin; Nilani Liyanage; Susan Pitman Lowenthal; Beloo Mirakhur; Rodney F Pommier; Montaser Shaheen; Aaron Vinik
Journal:  Oncologist       Date:  2017-10-16

3.  Diabetic neuropathy is associated with increased pain perception, low serum beta-endorphin and increase insulin resistance among Nigerian cohorts in Ekiti State.

Authors:  Olabode O Akintoye; Bamidele V Owoyele; Oyesanmi A Fabunmi; Taiwo H Raimi; Adesola A Oniyide; Abimbola O Akintoye; Ayodeji J Ajibare; David D Ajayi; Gbenga S Adeleye
Journal:  Heliyon       Date:  2020-07-11

4.  Relationship between somatostatin receptor expressing tumour volume and health-related quality of life in patients with metastatic GEP-NET.

Authors:  Håkan Ohlsson; Anni Gålne; Elin Trägårdh; Marlene Malmström; Anna Sundlöv; Martin Almquist
Journal:  J Neuroendocrinol       Date:  2022-04-29       Impact factor: 3.870

5.  Association between general self-efficacy, social support, cancer-related stress and physical health-related quality of life: a path model study in patients with neuroendocrine tumors.

Authors:  Trude Haugland; Astrid Klopstad Wahl; Dag Hofoss; Holli A DeVon
Journal:  Health Qual Life Outcomes       Date:  2016-01-19       Impact factor: 3.186

Review 6.  Diabetic Neuropathy: A Position Statement by the American Diabetes Association.

Authors:  Rodica Pop-Busui; Andrew J M Boulton; Eva L Feldman; Vera Bril; Roy Freeman; Rayaz A Malik; Jay M Sosenko; Dan Ziegler
Journal:  Diabetes Care       Date:  2017-01       Impact factor: 19.112

Review 7.  Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review.

Authors:  I Chau; R Casciano; J Willet; X Wang; J C Yao
Journal:  Eur J Cancer Care (Engl)       Date:  2013-07-29       Impact factor: 2.520

8.  Update on the Management of Diabetic Neuropathy.

Authors:  Lynn Ang; Nathan Cowdin; Kara Mizokami-Stout; Rodica Pop-Busui
Journal:  Diabetes Spectr       Date:  2018-08

9.  Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.

Authors:  James X Chen; E Paul Wileyto; Michael C Soulen
Journal:  Trials       Date:  2018-07-17       Impact factor: 2.279

Review 10.  Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes.

Authors:  Cristina Saavedra; Jorge Barriuso; Mairéad G McNamara; Juan W Valle; Angela Lamarca
Journal:  Cancer Manag Res       Date:  2019-08-08       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.